Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Supplement Enforcement Priorities Go Beyond NDI Notification

This article was originally published in The Tan Sheet

Executive Summary

FDA’s plan to tighten enforcement of new dietary ingredient notifications with its controversial guidance still in draft form raises concerns for some stakeholders.

You may also be interested in...



FDA Will Raise Bar For Supplement GMP Compliance – NPA

“FDA is training their inspectors faster than, I think, we’re training the industry,” says Natural Products Association VP Cara Welch. The regulatory affairs exec tells an Expo East audience the rate of supplement GMP inspections that observe violations remains unacceptably high.

FDA Will Raise Bar For Supplement GMP Compliance – NPA

“FDA is training their inspectors faster than, I think, we’re training the industry,” says Natural Products Association VP Cara Welch. The regulatory affairs exec tells an Expo East audience the rate of supplement GMP inspections that observe violations remains unacceptably high.

Regulatory News In Brief

FDA warns Healing Ways to register facility; Dragon Herbs warned for tradeshow materials; BNE recalls ephedra-spiked supplements; supplement flu prevention claims cross the line; more regulatory news in brief.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS105380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel